Tri-Med announces expansion into the Americas market
Released on : Nov. 22, 2023
Tri-Med is excited to announce the acquisition of global distribution rights for PYtest, the Urea Breath Test. In addition to its existing markets throughout the Asia Pacific Region and the Middle East, the acquisition grants Tri-Med access to the United States, Canadian and South American markets.
PYtest is the original urea breath test invented by founder of Tri-Med, Professor Barry Marshall. Professor Marshall famously won a Nobel Prize in Medicine, with Robin Warren, for discovering the causative link between Helicobacter pylori and stomach ulcers. PYtest is an essential enabler to assist Tri-Med in meeting its core purpose being the “detection and treatment of Helicobacter pylori globally.”
Professor Marshall expressed his excitement about the new developments, “I am ecstatic that Tri-Med has acquired global distribution rights for the product. I still fondly remember the original FDA trials we conducted in Charlottesville all those years ago. It is like welcoming a child back into the family!”
Tri-Med would like to acknowledge the support of regulatory consultant Chip Currey and the Immune Inc. team, who have advised on the transaction and subsequent licensing requirements and its 3PL, Reliable Healthcare Logistics who will assume responsibility for distribution throughout the Americas.
All enquiries can be made by emailing [email protected]
About Tri-Med:
Tri-Med’s purpose is to facilitate the detection and treatment of H.pylori globally. Tri-Med is a Global business founded in 1996 by Professor Barry Marshall to satisfy a need for the design, development, and distribution of a safe, reliable diagnostic test to detect H.pylori. Since these humble beginnings Tri-Med has expanded both its product base and international footprint and now markets its products throughout Australia and to a worldwide market including over 30 export destinations. Kindly log on to www.trimedamericas.com for more information about the organisation.